![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Cabotegravir (CAB) Long-Acting (LA)
Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-Infected Adults
|
|
|
HIVR4P: Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077 - (10/25/18)  
HIVR4P: Tail-phase safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected individuals: HPTN 077 final results - - (10/25/18)  
During Q&A which you can g=here on webcast question was asked about using oral CAB during injection interruptions and response was yes this can e accommodated and will be in FDA submission & indications.  
Reported by Jules Levin
HIVR4P - HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid  
Kelong Han,1 Parul Patel,2 Mark Baker,3 David Margolis,2 William Spreen,2 Alex Rinehart,2 Raphael Landovitz,4 Susan Ford5  
WEBCAST:
http://webcasts.hivr4p.org/console/player/40423?mediaType=slideVideo&&crd_fl=1&ssmsrq=1540731797528&ctms=5000&csmsrq=905
![1030181](../images%20/103018/103018-1/1030181.gif)
![1030182](../images%20/103018/103018-1/1030182.gif)
![1030183](../images%20/103018/103018-1/1030183.gif)
![1030184](../images%20/103018/103018-1/1030184.gif)
![1030185](../images%20/103018/103018-1/1030185.gif)
![1030186](../images%20/103018/103018-1/1030186.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|